Beasley R, Chang AB. Is tezepelumab the ubiquitous biologic for severe asthma? Lancet Respir Med 2023; published online Jan 23. https://doi.org/10.1016/S2213-2600(22)00530-6—In this Comment, the last sentence of the sixth paragraph should read “Therefore, patients should receive a trial of the simple and relatively inexpensive ICS–formoterol maintenance and reliever therapy before initiation of biologic therapies.” This correction has been made to the online version as of Feb 3, 2023, and will be made to the printed version.